The Cystic Fibrosis Foundation (CFF) has given Kinnear Pharmaceuticals up to $3 million to conduct the laboratory tests of CSA-131, a potential inhaled treatment of infections in people with cystic fibrosis (CF), that are needed to move it into human trials. CF patients are prone to bacterial lung infections. According to the CFF’s Patient Registry Report, 44.2% of enrolled patients — especially older adolescents and adults — were infected with Pseudomonas aeruginosa, a hard-to-treat bacteria, in 2019.…

You must be logged in to read/download the full post.